{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:22:01Z","timestamp":1781108521442,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.cpcardiol.2020.100552","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:50:43Z","timestamp":1582141843000},"page":"100552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acute Myocardial Infarction Due to Antiphospholipid Syndrome \u2013 Case Report and Review of the Literature"],"prefix":"10.1016","volume":"46","author":[{"given":"Karolina","family":"Semczuk-Kaczmarek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Platek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ry\u015b-Czaporowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip M.","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2020.100552_bib0001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13317-011-0017-9","article-title":"Pathophysiology of the antiphospholipid antibody syndrome","volume":"2","author":"Willis","year":"2011","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0002","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2174\/157016111796642715","article-title":"Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome","volume":"9","author":"Amengual","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0003","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0004","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) Morbidity and mortality in the antiphospholipid syndrome during 10 years: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0005","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.081194","article-title":"Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and antiphospholipid syndrome with systemic lupus erythematosus","volume":"36","author":"Danowski","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0007","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0008","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0009","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies","volume":"14","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0011","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-018-0775-8","article-title":"Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?","volume":"20","author":"Zuo","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0013","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0014","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0015","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0016","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0017","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the Global Anti-Phospholipid Syndrome Score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort","volume":"49","author":"Radin","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0019","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.02.155","article-title":"The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction","volume":"240","author":"Radin","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","article-title":"Antiphospholipid syndrome and the heart: a case series and literature review","volume":"14","author":"Denas","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0021","first-page":"162","article-title":"Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding","volume":"18","author":"Khurram","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0022","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2020.100552_bib0023","unstructured":"Woller S.C. (2019) Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiPhospholipid Syndrome (ASTRO-APS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02295475. Accessed September 17, 2019."}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280620300293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280620300293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:22:47Z","timestamp":1758939767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280620300293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0146280620300293"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100552","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Myocardial Infarction Due to Antiphospholipid Syndrome \u2013 Case Report and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100552"}}